FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088348749> ?p ?o ?g. }

• W3088348749 endingPage "S618" @default.
• W3088348749 startingPage "S618" @default.
• W3088348749 abstract "The phase III randomised VELIA study (NCT02470585) demonstrated significantly improved progression-free survival (PFS) with carboplatin/paclitaxel (CP) and veliparib (VEL) induction therapy followed by VEL maintenance vs CP alone (HR 0.44; 95% CI 0.28–0.68; Coleman et al., N Engl J Med 2019). Investigators chose between IV P 175 mg/m2 every 3 weeks (Q3W), or 80 mg/m2 dose-dense (DD) weekly. This exploratory analysis evaluated PFS and safety by P regimen. Patients received (1:1:1) CP + placebo followed by placebo maintenance (CP alone), or CP + VEL followed by placebo (VEL combination only), or CP + VEL followed by VEL (VEL throughout). Randomisation was stratified by P regimen and residual disease, disease stage, and region. Combination therapy was given for six 21-day cycles, followed by 30 cycles of VEL/placebo maintenance monotherapy. PFS was analysed using a Cox proportional hazards regression model. Among evaluable patients (N=1132), 52% received DD P; 48% received Q3W P. Cohorts were balanced for clinical characteristics and molecular signature (BRCA, homologous repair deficiency [HRD]). Median dose intensity ranged from 95%−99% with Q3W P and 84%−94% with DD P across treatment arms. Overall, DD P demonstrated longer PFS vs Q3W P (median: 20.5 vs 15.7 months; hazard ratio [HR] 0.77; 95% CI 0.66–0.89). The table shows effects of P regimen across subgroups and treatment arms. PFS was improved with VEL throughout vs CP alone, irrespective of P regimen. In the as-treated safety population (N=1124), Grade 3/4 adverse events were more frequent with DD P vs Q3W P, with rates of 90% vs 63% with CP alone, 94% vs 80% with VEL combination only, and 94% vs 82% with VEL throughout. In this exploratory analysis, DD P (+/- VEL) was associated with longer PFS overall and in biomarker-negative subgroups, and more frequent Grade 3/4 haematologic toxicities vs Q3W P in patients with newly diagnosed HGSOC." @default.
• W3088348749 created "2020-10-01" @default.
• W3088348749 creator A5009234043 @default.
• W3088348749 creator A5021359849 @default.
• W3088348749 creator A5024129361 @default.
• W3088348749 creator A5027894385 @default.
• W3088348749 creator A5028931954 @default.
• W3088348749 creator A5040185143 @default.
• W3088348749 creator A5043634794 @default.
• W3088348749 creator A5045166306 @default.
• W3088348749 creator A5046031005 @default.
• W3088348749 creator A5054602117 @default.
• W3088348749 creator A5055050872 @default.
• W3088348749 creator A5056238856 @default.
• W3088348749 creator A5056784491 @default.
• W3088348749 creator A5058244284 @default.
• W3088348749 creator A5063042904 @default.
• W3088348749 creator A5063378114 @default.
• W3088348749 creator A5066909949 @default.
• W3088348749 creator A5069337573 @default.
• W3088348749 creator A5069916605 @default.
• W3088348749 creator A5084420374 @default.
• W3088348749 date "2020-09-01" @default.
• W3088348749 modified "2023-10-17" @default.
• W3088348749 title "818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study" @default.
• W3088348749 doi "https://doi.org/10.1016/j.annonc.2020.08.957" @default.
• W3088348749 hasPublicationYear "2020" @default.
• W3088348749 type Work @default.
• W3088348749 sameAs 3088348749 @default.
• W3088348749 citedByCount "2" @default.
• W3088348749 countsByYear W30883487492021 @default.
• W3088348749 countsByYear W30883487492022 @default.
• W3088348749 crossrefType "journal-article" @default.
• W3088348749 hasAuthorship W3088348749A5009234043 @default.
• W3088348749 hasAuthorship W3088348749A5021359849 @default.
• W3088348749 hasAuthorship W3088348749A5024129361 @default.
• W3088348749 hasAuthorship W3088348749A5027894385 @default.
• W3088348749 hasAuthorship W3088348749A5028931954 @default.
• W3088348749 hasAuthorship W3088348749A5040185143 @default.
• W3088348749 hasAuthorship W3088348749A5043634794 @default.
• W3088348749 hasAuthorship W3088348749A5045166306 @default.
• W3088348749 hasAuthorship W3088348749A5046031005 @default.
• W3088348749 hasAuthorship W3088348749A5054602117 @default.
• W3088348749 hasAuthorship W3088348749A5055050872 @default.
• W3088348749 hasAuthorship W3088348749A5056238856 @default.
• W3088348749 hasAuthorship W3088348749A5056784491 @default.
• W3088348749 hasAuthorship W3088348749A5058244284 @default.
• W3088348749 hasAuthorship W3088348749A5063042904 @default.
• W3088348749 hasAuthorship W3088348749A5063378114 @default.
• W3088348749 hasAuthorship W3088348749A5066909949 @default.
• W3088348749 hasAuthorship W3088348749A5069337573 @default.
• W3088348749 hasAuthorship W3088348749A5069916605 @default.
• W3088348749 hasAuthorship W3088348749A5084420374 @default.
• W3088348749 hasBestOaLocation W30883487491 @default.
• W3088348749 hasConcept C126322002 @default.
• W3088348749 hasConcept C126894567 @default.
• W3088348749 hasConcept C141071460 @default.
• W3088348749 hasConcept C142724271 @default.
• W3088348749 hasConcept C204787440 @default.
• W3088348749 hasConcept C207103383 @default.
• W3088348749 hasConcept C27081682 @default.
• W3088348749 hasConcept C2776694085 @default.
• W3088348749 hasConcept C2778239845 @default.
• W3088348749 hasConcept C2781413609 @default.
• W3088348749 hasConcept C2781451048 @default.
• W3088348749 hasConcept C2908647359 @default.
• W3088348749 hasConcept C29456083 @default.
• W3088348749 hasConcept C44249647 @default.
• W3088348749 hasConcept C71924100 @default.
• W3088348749 hasConcept C99454951 @default.
• W3088348749 hasConceptScore W3088348749C126322002 @default.
• W3088348749 hasConceptScore W3088348749C126894567 @default.
• W3088348749 hasConceptScore W3088348749C141071460 @default.
• W3088348749 hasConceptScore W3088348749C142724271 @default.
• W3088348749 hasConceptScore W3088348749C204787440 @default.
• W3088348749 hasConceptScore W3088348749C207103383 @default.
• W3088348749 hasConceptScore W3088348749C27081682 @default.
• W3088348749 hasConceptScore W3088348749C2776694085 @default.
• W3088348749 hasConceptScore W3088348749C2778239845 @default.
• W3088348749 hasConceptScore W3088348749C2781413609 @default.
• W3088348749 hasConceptScore W3088348749C2781451048 @default.
• W3088348749 hasConceptScore W3088348749C2908647359 @default.
• W3088348749 hasConceptScore W3088348749C29456083 @default.
• W3088348749 hasConceptScore W3088348749C44249647 @default.
• W3088348749 hasConceptScore W3088348749C71924100 @default.
• W3088348749 hasConceptScore W3088348749C99454951 @default.
• W3088348749 hasLocation W30883487491 @default.
• W3088348749 hasOpenAccess W3088348749 @default.
• W3088348749 hasPrimaryLocation W30883487491 @default.
• W3088348749 hasRelatedWork W1983784941 @default.
• W3088348749 hasRelatedWork W2022084568 @default.
• W3088348749 hasRelatedWork W2059792707 @default.
• W3088348749 hasRelatedWork W2277847524 @default.
• W3088348749 hasRelatedWork W2356819079 @default.
• W3088348749 hasRelatedWork W2383272827 @default.
• W3088348749 hasRelatedWork W2390233036 @default.
• W3088348749 hasRelatedWork W2586977583 @default.
• W3088348749 hasRelatedWork W4231341789 @default.

• next